Drug resistance and epidemiology characteristics of multidrug-resistant tuberculosis patients in 17 provinces of China


Autoři: Zhenhui Lu aff001;  Wenhan Jiang aff002;  Jing Zhang aff002;  Henry S. Lynn aff002;  Yue Chen aff003;  Shaoyan Zhang aff001;  Zifeng Ma aff001;  Peihua Geng aff001;  Xiaoyan Guo aff001;  Huiyong Zhang aff001;  Zhijie Zhang aff002
Působiště autorů: Department of Respiratory, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China aff001;  Department of Epidemiology and Biostatistics, School of Public Health, Fudan University, Xuhui District, Shanghai, People’s Republic of China aff002;  School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada aff003
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
doi: 10.1371/journal.pone.0225361

Souhrn

As China is one of high MDR-TB burden countries, it is important to determine the drug resistant pattern and clinical characteristics of multidrug resistant tuberculosis (MDR-TB). We conducted a comprehensive and nationwide study on MDR-TB in 17 provinces for the period from June 2009 to June 2015, and a total of 1154 cases of MDR-TB were finally investigated. The study sought to assess the clinical features and contrast drug susceptibility profiles of MDR-TB patients in China. Cavitary disease, young age, and long duration of TB disease among MDR-TB patients were important predictors. A high resistance proportion of first-line drugs was observed in Beijing, Shanghai and Tianjin. Resistant proportions of second-line anti-TB drugs in western region for amikacin, aminosalicylic acid, and levofloxacin were higher than eastern and central regions. High levels of drug resistance were seen in earlier cases (before 2011) and outpatients. We found high levels of resistance to 1st- and 2nd-line drugs in all settings, with considerable variabilities in terms of different Directly Observed Treatment Short Course (DOTS) programme, level of economic development(eastern, central and western regions) and patient source (inpatients and outpatients). Timely drug susceptibility testing (DST) and effective management are necessary to ensure an early detection of MDR-TB and its proper treatment.

Klíčová slova:

Drug therapy – Extensively drug-resistant tuberculosis – China – Multi-drug-resistant tuberculosis – Outpatients – Streptomycin – Tuberculosis – Tuberculosis diagnosis and management


Zdroje

1. Jenkins HE, Plesca V, Ciobanu A, Crudu V, Galusca I, Soltan V, et al. Assessing spatial heterogeneity of MDR-TB in a high burden country. European Respiratory Journal. 2013;42(5).

2. Raviglione M. XDR-TB: entering the post-antibiotic era? International Journal of Tuberculosis & Lung Disease the Official Journal of the International Union Against Tuberculosis & Lung Disease. 2006;10(11):1185–7.

3. WHO. Global Tuberculosis Report 2018. Geneva: World Health Organization. 2018.

4. WHO. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization. 2019.

5. States U, Partnership STB, Committee GL. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs. Annals of Pharmacotherapy. 2006;40(5). https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5511a2.htm#top.

6. Jaramillo, Ernesto. Guidelines for the programmatic management of drug-resistant tuberculosis: World Health Organization, Stop TB Department; 2008.

7. The fifth national tuberculosis epidemiological survey in 2010. 2012.

8. Qi YC, Ma MJ, Li DJ, Chen MJ, Lu QB, Li XJ, et al. Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Multi-Ethnic Region, Xinjiang Uygur Autonomous Region, China. Plos One. 2012;7(2):e32103. doi: 10.1371/journal.pone.0032103 22384153

9. Sun Y, Harley D, Vally H, Sleigh A. Impact of Multidrug Resistance on Tuberculosis Recurrence and Long-Term Outcome in China. Plos One. 2017;12(1):e0168865. doi: 10.1371/journal.pone.0168865 28118372

10. Yuan X, Zhang T, Kazuyoshi K, Zhu J, Zheng W, Li H, et al. Genotyping and clinical characteristics of multidrug and extensively drug-resistant tuberculosis in a tertiary care tuberculosis hospital in China. BMC Infectious Diseases. 2013;13(1):315.

11. Tadesse M, Abebe G, Abdissa K, Bekele A, Bezabih M, Apers L, et al. Concentration of Lymph Node Aspirate Improves the Sensitivity of Acid Fast Smear Microscopy for the Diagnosis of Tuberculous Lymphadenitis in Jimma, Southwest Ethiopia. Plos One. 2014;9(9). ARTN e106726 doi: 10.1371/journal.pone.0106726 WOS:000341257700111. 25184279

12. Siddiqi S, Rueschgerdes S. MGIT procedure manual for BACTEC MGIT 960 TB System. 2006.

13. WHO. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva: World Health Organization. 2010;35(6):2171–8.

14. Wang L, Zhang H, Ruan Y, Chin DP, Xia Y, Cheng S, et al. Tuberculosis prevalence in China, 1990–2010; a longitudinal analysis of national survey data. Lancet. 2014;383(9934):2057. doi: 10.1016/S0140-6736(13)62639-2 24650955

15. Hoa NB, Khanh PH, Chinh NV, Hennig CM. Prescription patterns and treatment outcomes of MDR-TB patients treated within and outside the National Tuberculosis Programme in Pham Ngoc Thach hospital, Viet Nam. Tropical Medicine & International Health. 2014;19(9):1076–81.

16. Zhao M, Li X, Xu P, Shen X, Gui X, Wang L, et al. Transmission of MDR and XDR tuberculosis in Shanghai, China. Plos One. 2009;4(2):e4370. doi: 10.1371/journal.pone.0004370 19190774

17. Kuksa L, Riekstina V, Leimane V, Ozere I, Skenders G, Van dBR, et al. Multi- and extensively drug-resistant tuberculosis in Latvia: trends, characteristics and treatment outcomes. Public Health Action. 2014;4(2):47–53.

18. He XC, Zhang XX, Zhao JN, Liu Y, Yu CB, Yang GR, et al. Epidemiological Trends of Drug-Resistant Tuberculosis in China From 2007 to 2014: A Retrospective Study. Medicine. 2016;95(15):e3336. doi: 10.1097/MD.0000000000003336 27082586

19. Eker B, Ortmann J, Migliori GB, Sotgiu G, Muetterlein R, Centis R, et al. Multidrug- and extensively drug-resistant tuberculosis, Germany: Kluwer Academic Pub; 2008. 1700–6 p. doi: 10.1016/j.tube.2008.07.004

20. Organization WH. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva Switzerland Who. 2010;35(6):2171–8.

21. Cui HL, Ling L, Zhi C, Qi W, Yong LH, Zhu B, et al. Characteristics and Treatment Outcomes of Patients with MDR and XDR Tuberculosis in a TB Referral Hospital in Beijing: A 13-Year Experience. Plos One. 2011;6(4):e19399. doi: 10.1371/journal.pone.0019399 21559362

22. Temple B, Ayakaka I, Ogwang S, Nabanjja H, Kayes S, Nakubulwa S, et al. Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda. Clinical infectious diseases. 2008;47(9):1126–34. doi: 10.1086/592252 18808360

23. Liang L, Wu Q, Gao L, Hao Y, Liu C, Xie Y, et al. Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China. Thorax. 2012:thoraxjnl-2011-200018.

24. WHO. Guidelines for the programmatic management of drug-resistant tuberculosis-2011 update. Geneva: World Health Organization. 2011;WHO/HTM/TB/2011.6.

25. Devasia RA, Blackman A, Gebretsadik T, Griffin M, Shintani A, May C, et al. Fluoroquinolone Resistance in Mycobacterium tuberculosis: The Effect of Duration and Timing of Fluoroquinolone Exposure. American Journal of Respiratory & Critical Care Medicine. 2009;180(4):365.

26. Zhang X, Yin J, Li H, Li S, Walley J, Zou G, et al. Diagnostic and treatment delays of multidrug‐resistant tuberculosis before initiating treatment: a cross‐sectional study. Tropical Medicine & International Health. 2015;20(11):1431–7.

27. Chen Y, Yuan Z, Shen X, Wu J, Wu Z, Xu B. Resistance to Second-Line Antituberculosis Drugs and Delay in Drug Susceptibility Testing among Multidrug-Resistant Tuberculosis Patients in Shanghai. Biomed Research International. 2016;2016(5):2628913.

28. Paramasivan CN, Rehman F, Wares F, Sundar MN, Sundar S, Devi S, et al. First- and second-line drug resistance patterns among previously treated tuberculosis patients in India. International Journal of Tuberculosis & Lung Disease the Official Journal of the International Union Against Tuberculosis & Lung Disease. 2010;14(2):243–6.

29. Liu Y, Tang S. Analysis of first and second line anti-tuberculosis drugs resistance of mycobacterium tuberculosis in Shanghai. Chinese Journal of Infectious Diseases. 2011;29(9):544–8.

30. Collaboration CTC. The effect of tuberculosis control in China. The Lancet. 2004;364(9432):417–22. http://dx.doi.org/10.1016/S0140-6736(04)16764-0.

31. Lönnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, et al. Tuberculosis control and elimination 2010–50: cure, care, and social development. Lancet. Lancet. 2010;375(9728):1814. doi: 10.1016/S0140-6736(10)60483-7 20488524

32. Wang L, Liu J, Chin DP. Progress in tuberculosis control and the evolving public-health system in China. Lancet. 2007;369(9562):691. http://www.doc88.com/p-9929562891254.html. doi: 10.1016/S0140-6736(07)60316-X 17321314

33. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System. International Journal of Tuberculosis & Lung Disease the Official Journal of the International Union Against Tuberculosis & Lung Disease. 2008;12(12):1449–55.

34. Tam KKG, Leung KSS, Siu GKH, Chang KC, Wong SSY, Ho PL, et al. Direct Detection of Pyrazinamide Resistance in Mycobacterium tuberculosis by Use of pncA PCR Sequencing. J Clin Microbiol. 2019;57(8). UNSP e00145-19 doi: 10.1128/JCM.00145-19 WOS:000477738500003. 31189582


Článek vyšel v časopise

PLOS One


2019 Číslo 11